Editor's Pick: The week ahead....
(SEO.L) Stanelco PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 09-11-09 | RNS |
|
|
RNS Number : 1835C Stanelco PLC 09 November 2009 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
of existing shares to which voting rights are
attached: ii
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial
instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the
notification obligation: iii
4. Full name of shareholder(s)
(if different from 3.):iv
5. Date of the transaction and date on
which the threshold is crossed or
reached: v
6. Date on which issuer notified:
7. Threshold(s) that is/are crossed or
reached: vi, vii
8. Notified details:
A: Voting rights attached to shares viii, ix
if possible using
the ISIN CODE
GB0005814198
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Total (A+B+C)
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:
14. Contact name: 020 7658 6000 15. Contact telephone number: This information is provided by RNS The company news service from the London Stock Exchange END
HOLFSLFSUSUSESF More |
||
| 06-11-09 | RNS |
|
This news article is displayed preformatted as it may contain results tables
RNS Number : 0801C
Stanelco PLC
06 November 2009
6 November 2009
Stanelco plc ("the Company" or "the Group")
Interim Management Statement
Stanelco plc issues its interim management statement for the period from 1 January 2009 to 5 November 2009, as required by the UK Listing Authority's Disclosure and Transparency Rules.
Highlights
* Sales to 30 September up 12% to £13.4m
* Trading performance in line with Board's expectations:
* Continued growth in bioplastics division driven by interest in adopting sustainable products; increasing applications in new sectors
* Radio frequency applications division sales order pipeline continued to strengthen; growing overseas sales in China and India
* Closing cash position at 30 September £3.7m, increased by working capital improvements
* Board confident in full year outlook
Trading Update
Group revenues grew strongly during the nine months to 30 September 2009 and the Group's overall trading performance was in line with the Board's expectations.
Group revenues increased from £12.0m to £13.4m in the nine months to 30 September 2009, an increase of 12% compared with the same period last year. This reflected a 29% increase in bioplastic sales made directly by the Company, a 30% increase in sales in RF Applications division and an 8% increase in third party sales from our joint venture, Biotec.
Our cash position at 30 September 2009 was £3.7m, strengthened since the half year by working capital improvements, including a reduction in stock levels following the summer production holiday.
Bioplastics division
In the Bioplastics division, the sales team that was established last year has had a number of successes in growing sales of the Group's existing biodegradable products into the market, delivering a 29% increase in the Company's bioplastic sales in the nine months to 30 September 2009. The division has broadened its customer base with over 40 new customers in 2009 and widened the set of end-use applications by a further 17 in the same period. The management remain encouraged by the division's opportunities for growth.
The product development team continues to work closely with a number of blue chip customers and mainstream plastics convertors to develop a widening range of biodegradable products that can substitute oil-based plastics. Whilst some of these development paths are still at an early stage, others are poised to deliver further growth in the coming months. The development team continues to focus on those accounts which we consider could have the maximum growth potential.
We continue to see strong demand for bioplastic products in the market, driven not only by concerns about waste disposal but also by the desire of many large corporations to switch to using sustainable resources in key brands. This switch to the use of "renewable" materials in advance of legislation is seen as both a branding enhancement and a hedge against further oil based price rises. Sectors in which we are gaining traction include packaging, waste disposal, paper products, personal care, horticulture and electronics. The sales development work undertaken in the USA over the past year is now also gaining momentum.
Our joint venture, Biotec, delivered 8% growth in its third party sales for the 9 months to 30 September 2009 compared with the same period last year.
Radio Frequency (RF) applications division
In the RF Applications division, the team has been fulfilling a number of significant orders that have been won in the nine months to 30 September 2009, including the £0.3m order for RF furnaces disclosed in our interim results. Sales in the period increased by 30% compared with the same period last year including growth in both optical fibre furnaces and more general industrial equipment in which we are building a portfolio of customers making repeat orders. The sales order pipeline continues to strengthen with a particular emphasis on sales in India and China. As a result, a new sales consultant has now been appointed for Stanelco dedicated to the Indian market, as this territory shows signs of increasing growth in the next few years.
Outlook
The Board continues to be confident in the outlook for the full year. Our focus continues to be on working closely with customers with the potential to deliver increases in revenue, whilst considering acquisition opportunities and other paths that could significantly increase the scale of the business and deliver shareholder value.
- Ends -
For further information please contact:
Paul Mines, Chief Executive, Stanelco plc Tel: +44 (0) 2380 867100
Sue Bygrave, Group Finance Director, Stanelco plc
Jonathon Brill/Caroline Stewart, Tel: +44 (0) 20 7831 3113
Financial Dynamics
This information is provided by RNS
The company news service from the London Stock Exchange
END
IMSBABRTMMJMBFL
More |
||
| 21-10-09 | RNS |
|
|
RNS Number : 1761B Stanelco PLC 21 October 2009 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
of existing shares to which voting rights are
attached: ii
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of qualifying financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial
instruments
An event changing the breakdown of voting rights
Other (please specify):
notification obligation: iii
4. Full name of shareholder(s)
(if different from 3.):iv
which the threshold is crossed or
reached: v
reached: vi, vii
8. Notified details:
A: Voting rights attached to shares viii, ix
if possible using
the ISIN CODE
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Total (A+B+C)
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi Barclays Stockbrokers Ltd Gerrard Investment Management Ltd Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
This information is provided by RNS The company news service from the London Stock Exchange END
HOLFELFLFSUSEFS More |
||
| 20-10-09 | RNS |
|
|
RNS Number : 1119B Stanelco PLC 20 October 2009 Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security during the initial auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the last automated execution today. The applicable percentage is set by reference to a security's TradElect sector. This is set out in the Sector Breakdown tab of the TradElect Parameters document at www.londonstockexchange.com/en-gb/products/membershiptrading/tradingservices</f ipP> This information is provided by RNS The company news service from the London Stock Exchange END
PMEPUGAWUUPBGAU More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 20:03 | ||||
|
| ||||
|
| ||||
| 20:02 | ||||
|
| ||||
|
| ||||
|
With gross margins of around 20% by how much will sales have to increase over the £14.8m sales last year in order to cover the £2.8m loss reported last year? We need sales of around £30m to get to breakeven! There will be fundrasing and further dilution before this company gets near breakeven, let alone acquisition. Let's see what happens on 3 December at the EPO, if we lose its really bad news. I'm waiting until I buy more, IMHO this has not bottomed out.
Blood More | View thread (4) | Respond | Login to Vote up | Login to Vote down |
||||
| 17:15 |
BUY
Re: Golden share
|
|||
|
| ||||
|
| ||||
|
sales of bioplastics made directly by stanelco went up 385% from a year earlier was reported in march 09 results so if this trend continues then i wouldnt worry about losing the 50% golden share....here's why:
Stanelco's direct sales of bioplastics increased from GBP0.4m in 2007 to GBP1.8m in 2008 as a new commercial team began to build the customer relationships and trust that are essential for commercialising this technology. The end-uses in which Stanelco's bioplastics are now found (or are being trialled for) increased considerably in the year. Our materials can now be found in flexible films, horticultural products, bottles and tubes, fibres, capsules and injection-moulded items to name just a few. so if that trend continues we'll generate revenues of around £6mish next march results and because we are directly selling the product margins will increase..total revenue should still be higher even though we lose half share of revenues at Biotec BECAUSE apparently sales there are booming...its a no brainer guys so fill ya skullcaps! More | View thread (4) | Respond | Login to Vote up | Login to Vote down |
||||
| 11:56 | ||||
|
| ||||
|
| ||||
|
???????????????????????
More | View thread (4) | Respond | Login to Vote up | Login to Vote down |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...